



US010280208B2

(12) **United States Patent**
Zang et al.

(10) **Patent No.:** **US 10,280,208 B2**

(45) **Date of Patent:** **May 7, 2019**

(54) **TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIES**

(71) Applicant: **ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.**, Bronx, NY (US)

(72) Inventors: **Xingxing Zang**, New York, NY (US); **Jordan M. Chinai**, Bronx, NY (US); **Murali Janakiram**, Brooklyn, NY (US); **Steven C. Almo**, Pelham, NY (US); **Andras Fiser**, New York, NY (US)

(73) Assignee: **Albert Einstein College of Medicine**, Bronx, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **15/300,294**

(22) PCT Filed: **Apr. 24, 2015**

(86) PCT No.: **PCT/US2015/027429**

§ 371 (c)(1),

(2) Date: **Sep. 29, 2016**

(87) PCT Pub. No.: **WO2015/167948**

PCT Pub. Date: **Nov. 5, 2015**

(65) **Prior Publication Data**

US 2017/0174742 A1 Jun. 22, 2017

Related U.S. Application Data

(60) Provisional application No. 61/986,238, filed on Apr. 30, 2014.

(51) **Int. Cl.**

C07K 14/70 (2006.01)

C07K 14/705 (2006.01)

A61K 38/00 (2006.01)

(52) **U.S. Cl.**

CPC **C07K 14/70503** (2013.01); **A61K 38/00** (2013.01); **C07K 2319/30** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

9,447,186 B2 9/2016 Zang et al.
2007/0122406 A1* 5/2007 Chamberlain C07K 16/30 424/144.1
2016/0002337 A1 1/2016 Zang

FOREIGN PATENT DOCUMENTS

WO 2007039507 A2 4/2007
WO 2011020024 A2 2/2011
WO WO 2011/020024 * 2/2011 C07K 14/705
WO 2012075184 A2 6/2012
WO 2013049254 A1 4/2013
WO 2015094782 A1 6/2015
WO 2016085662 A1 6/2016

OTHER PUBLICATIONS

Zhao et al. (PNAS, 110(24): 9879-9884, 2013).*
Bauer et al. (Cancer, 109(9):1721-1728, 2007).*
International Search Report and Written Opinion, dated Aug. 14, 2015 in connection with PCT International Application No. PCT/US2015/27429, 10 pages.

* cited by examiner

Primary Examiner — Nelson B Moseley, II
(74) *Attorney, Agent, or Firm* — Amster, Rothstein & Ebenstein LLP

(57) **ABSTRACT**

Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.

14 Claims, 3 Drawing Sheets

Specification includes a Sequence Listing.